NUVB · Nuvation Bio Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-15 | Sauvage Philippe |
Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of February 28, 2025, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
1 |
| 2026-07-15 | Sauvage Philippe |
Chief Financial Officer |
Convert↑
Filing footnotes — Class A Common Stock (Direct)
Includes 1,458 shares purchased through the issuer's employee stock purchase plan on May 19, 2026. |
Class A Common Stock
|
1 |
| 2026-07-15 | Sauvage Philippe |
Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of October 7, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
39,999 |
| 2026-07-15 | Sauvage Philippe |
Chief Financial Officer |
Convert↑
Filing footnotes — Class A Common Stock (Direct)
Includes 1,458 shares purchased through the issuer's employee stock purchase plan on May 19, 2026. |
Class A Common Stock
|
39,999 |
| 2026-06-23 | Markel Stacy |
CHIEF PEOPLE OFFICER |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.085. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
125,000 |
| 2026-06-23 | Markel Stacy |
CHIEF PEOPLE OFFICER |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on September 30, 2020 and in equal monthly installments thereafter over the following three years, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
34,620 |
| 2026-06-23 | Sauvage Philippe |
Chief Financial Officer |
Convert↑
|
Class A Common Stock
|
47,668 |
| 2026-06-23 | Sauvage Philippe |
Chief Financial Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.04. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
47,668 |
| 2026-06-23 | Wentworth Kerry |
CHIEF REGULATORY OFFICER |
Convert↑
|
Class A Common Stock
|
63,000 |
| 2026-06-23 | Markel Stacy |
CHIEF PEOPLE OFFICER |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of February 29, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
90,380 |
| 2026-06-23 | Wentworth Kerry |
CHIEF REGULATORY OFFICER |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.08. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
63,000 |
| 2026-06-23 | Markel Stacy |
CHIEF PEOPLE OFFICER |
Convert↑
|
Class A Common Stock
|
90,380 |
| 2026-06-23 | Wentworth Kerry |
CHIEF REGULATORY OFFICER |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of August 29, 2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
63,000 |
| 2026-06-23 | Markel Stacy |
CHIEF PEOPLE OFFICER |
Convert↑
|
Class A Common Stock
|
34,620 |
| 2026-06-23 | Sauvage Philippe |
Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of October 7, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
47,668 |
| 2026-06-09 | Mashal Robert |
Director |
Buy↑
Filing footnotes — Class A Common Stock (Indirect)
Shares are owned directly by the Robert D. Mashal 2020 Revocable Trust, of which Reporting Person is the sole trustee. |
Class A Common Stock
(I)
|
25,000 |
| 2026-05-21 | Mashal Robert |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. |
Stock Option (Right to Buy)
|
123,397 |
| 2026-05-21 | FALBERG KATHRYN E |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. |
Stock Option (Right to Buy)
|
123,397 |
| 2026-05-21 | Bazemore Robert B |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. |
Stock Option (Right to Buy)
|
123,397 |
| 2026-05-21 | BLICKENSTAFF KIM D |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. |
Stock Option (Right to Buy)
|
123,397 |
| 2026-05-21 | Cui Xiangmin |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. |
Stock Option (Right to Buy)
|
123,397 |
| 2026-05-21 | VERNON W ANTHONY |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. |
Stock Option (Right to Buy)
|
123,397 |
| 2026-04-17 | Liu Dongfang |
CHIEF MEDICAL OFFICER |
Convert↑
|
Class A Common Stock
|
50,000 |
| 2026-04-17 | Wentworth Kerry |
CHIEF REGULATORY OFFICER |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $5.00 to $5.05. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
36,750 |
| 2026-04-17 | Wentworth Kerry |
CHIEF REGULATORY OFFICER |
Convert↑
|
Class A Common Stock
|
36,750 |
| 2026-04-17 | Wentworth Kerry |
CHIEF REGULATORY OFFICER |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of August 29, 2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
36,750 |
| 2026-04-17 | Liu Dongfang |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $5.00 to $5.07. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
50,000 |
| 2026-04-17 | Liu Dongfang |
CHIEF MEDICAL OFFICER |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on February 28, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date |
Stock Option (Right to Buy)
|
50,000 |
| 2026-04-06 | Wentworth Kerry |
CHIEF REGULATORY OFFICER |
Convert↑
|
Class A Common Stock
|
100,000 |
| 2026-04-06 | Wentworth Kerry |
CHIEF REGULATORY OFFICER |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
100,000 |
| 2026-04-06 | Wentworth Kerry |
CHIEF REGULATORY OFFICER |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
100,000 |
| 2026-04-06 | Wentworth Kerry |
CHIEF REGULATORY OFFICER |
Convert↑
|
Class A Common Stock
|
100,000 |
| 2026-04-06 | Wentworth Kerry |
CHIEF REGULATORY OFFICER |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $4.44 to $4.64. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
200,000 |
| 2026-02-27 | Hung David |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
1,995,012 |
| 2026-02-27 | Hattersley Gary |
CHIEF SCIENTIFIC OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
748,130 |
| 2026-02-27 | Wentworth Kerry |
CHIEF REGULATORY OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
748,130 |
| 2026-02-27 | Sjogren Colleen |
Chief Commercial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
748,130 |
| 2026-02-27 | Sauvage Philippe |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
748,130 |
| 2026-02-27 | Cui Xiangmin |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 3, 2026, the reporting person filed a Form 4 which, due to an administrative error, incorrectly reported that the reporting person was awarded 74,813 options to purchase Class A Common Stock on February 27, 2026. In fact, the reporting person was awarded 76,923 options to purchase Class A Common Stock on such date. Option vests as to 1/24 of the shares on the one month anniversary of 1/1/2026, monthly thereafter over the following 23 months, subject to Reporting Person's continuous service on each such vesting date |
Stock Option (Right to Buy)
|
76,923 |
| 2026-02-27 | Markel Stacy |
CHIEF PEOPLE OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
748,130 |
| 2026-02-27 | Hanley David C. |
CHIEF TECHNICAL OPERATIONS |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
748,130 |
| 2026-02-27 | Liu Dongfang |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
748,130 |
| 2026-02-27 | Makunje Moses |
SEE REMARKS |
Award↑
Filing footnotes — Class A Common Stock (Direct)
Represents the grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock upon settlement. 25% of the shares subject to the RSUs shall vest on the Issuer's quarterly vesting date following each of the first four anniversaries from 2/27/2026, subject to Reporting Person's continuous service on each such vesting date. Includes 1,001 shares acquired on May 19, 2025 and 1,100 shares acquired November 19, 2025 under the 2021 Employee Stock Purchase Plan. |
Class A Common Stock
|
50,761 |
| 2026-02-27 | Makunje Moses |
SEE REMARKS |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vests as to 25% on the one year anniversary of 2/27/26, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
224,439 |
| 2025-12-01 | Liu Dongfang |
CHIEF MEDICAL OFFICER |
Convert↑
|
Class A Common Stock
|
150,000 |
| 2025-12-01 | Liu Dongfang |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.80 to $7.855. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
150,000 |
| 2025-12-01 | Liu Dongfang |
CHIEF MEDICAL OFFICER |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vested as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date |
Stock Option (Right to Buy)
|
150,000 |
| 2025-11-26 | Liu Dongfang |
CHIEF MEDICAL OFFICER |
Convert↑
|
Class A Common Stock
|
10,000 |
| 2025-11-26 | Liu Dongfang |
CHIEF MEDICAL OFFICER |
Sell↓
|
Class A Common Stock
|
10,000 |
| 2025-11-26 | Liu Dongfang |
CHIEF MEDICAL OFFICER |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Option vested as to 25% on the one year anniversary of 7/15/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Stock Option (Right to Buy)
|
10,000 |